One-Year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis in a canadian population

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue 2, 2013, Pages 129-138

  Vender, Ronald ^{a,b,c,d,e,f,g,h}   Lynde, Charles ^{a,b,c,d,e,f,g,h}   Gilbert, Martin ^{a,b,c,d,e,f,g,h}   Ho, Vincent ^{a,b,c,d,e,f,g,h}   Sapra, Sheetal ^{a,b,c,d,e,f,g,h}   Poulin Costello, Melanie ^{a,b,c,d,e,f,g,h}  

^a Dermatrials Research   (Canada)

^b Lynde Centre for Dermatology Canada   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Skin Care Centre   (Canada)

^g Institute of Cosmetic and Laser Surgery   (Canada)

^h Amgen Canada Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; AORTA STENOSIS; ARTICLE; BASAL CELL CARCINOMA; BODY SURFACE; CANADA; CELLULITIS; CONGESTIVE HEART FAILURE; CONVULSION; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FEMALE; FLUID RETENTION; HEADACHE; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SUBDURAL HEMATOMA; THYROID ADENOMA; THYROID CANCER; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; CANADA; CONFIDENCE INTERVALS; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NASOPHARYNGITIS; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 84876937002     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2012.12036     Document Type: Article

References (19)

1. Bonifati C, Carducci M, Cordiali FP, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte- colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994;19:383-7, doi:10.1111/j.1365-2230.1994.tb02687.x.
2. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51, doi:10.1111/j.1365-2249.1994.tb06244.x.
3. Ameglio F, Bonifati C, Pietravalle M, Fazio M. Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 1994; 189:359-63, doi:10.1159/000246879.
4. EnbrelH (etanercept) [product monograph]. Mississauga (ON): Amgen Canada; 2010.
5. Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007;156:138-42, doi:10.1111/j.1365- 2133.2006. 07585.x.
6. Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53: 887-9, doi:10.1016/j.jaad.2005.06.053.
7. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008;11:400-7, doi:10.1111/j.1524- 4733.2007.00251.x.
8. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139: 1627-32, doi:10.1001/archderm.139.12.1627.
9. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153: 1192-9, doi:10.1111/j.1365-2133.2005.06948.x.
10. Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010;9:928-37.
11. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349: 2014-22, doi:10.1056/ NEJMoa030409.
12. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56:598-603, doi:10.1016/j.jaad.2006.09.002.
13. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-212, doi:10.1111/j.1365-2133.2005. 06688.x.
14. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the longterm safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012;66: e33-45, doi:10.1016/j.jaad.2010. 07.026.
15. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367: 29-35, doi:10.1016/S0140-6736(05)67763-X.
16. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26, doi:10.1001/archderm.143.6.719.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6, doi:10.1111/j.1365-2230.1994.tb01167.x.
18. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147 Suppl 62:25-54.
19. Feldman SR, Kimball A, Woolley JM. Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis. J Am Acad Dermatol 2004;50 Suppl 1:155, doi:10.1016/j.jaad.2003.10.543.